XTAI
4108
Market cap71mUSD
Oct 08, Last price
11.55TWD
1D
1.76%
1Q
-3.75%
Jan 2017
-62.19%
IPO
-71.57%
Name
Phytohealth Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1998 and headquartered in Taipei, Taiwan, PhytoHealth Corporation specializes in the research, development, production, and commercialization of a diverse portfolio including pharmaceutical products, cosmetic lines, specific over-the-counter medications (Class B), and nutritional supplements. Their prominent offerings feature the PG2 Lyophilized injection, specifically designed to alleviate cancer-related fatigue. The company also markets EnerCharge, available both as a formula to boost physical vigor and maintain mental alertness, and as an energy beverage. Another notable product is ReyeasCleanse health food capsules. Furthermore, PhytoHealth extends its expertise to precision medical devices, specialized diagnostic software, and licensing services for computer-aided diagnostic systems.
Key people
Chairman of the Board · since 2020
Zhiyuan Huang
Corporate Governance Officer · since 2023
Yinshou Lin
Head-Finance & Accounting · since 2007
Jingzhong Cai
Director
Zehong Huang
Director · since 2020
Director · since 2011
Director · since 2011
Director · since 2021
Vice Chairman of the Board, General Manager · since 2021
Mingfu Wang
Director · since 2017
Bosen Wang
Director · since 2022
Jinghui You
Director · since 2017
Independent Director · since 2017
Shuilong Lin
Independent Director · since 2020
Yang-Chang Wu
Independent Director · since 2023
IPO date
May 07, 2002
Employees
Domiciled in
TW
Incorporated in
TW
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||